Abstract

Study Design: Retrospective interventional case series.
Purpose: To describe treatment outcomes in patients with fine needle aspiration biopsy (FNAB) proven primary choroidal lymphoma treated with ultra-low-dose (4 Gray) radiotherapy.
Methods: All patients underwent transvitreal FNAB using 27-gauge needle through the pars plana and after cytopathology confirmation of lymphoma, each patient was treated with ultra-low-dose radiotherapy of 4 Gray over 2 days.
Results: The mean follow-up was 33.5 months. A comparison (pre- vs. post-radiotherapy) showed improvement in mean best corrected LogMAR visual acuity (p=0.02), reduction in mean choroidal thickness (p=0.03) and reduction in mean central macular thickness (p=0.04). One patient demonstrated tumor recurrence (n=1, 12.5%) after 36 months. There were no radiation-related major complications.
Conclusion: Ultra-low-dose radiotherapy with 4 Gray is safe and effective for primary choroidal lymphoma with tumor control in nearly all cases.